Cancer Surges Across US Adults

A recent analysis reveals a troubling trend: colorectal cancer incidence rates are increasing across nearly all adult age groups in the United States, marking the first overall rise in incidence in over 20 years. While incidence rates for adults aged 20-49 increased by 3% annually between 2013 and 2022, the new data indicates a broader rise affecting older demographics as well. Researchers are investigating potential environmental risk factors that may be contributing to this shift.

In parallel, promising data from a mid-stage trial suggests a combination of two targeted therapy drugs can significantly improve survival for certain patients with newly diagnosed advanced kidney cancer. This regimen, comprising Votrient and Avastin, offers an alternative to more costly immunotherapies, especially for patients with autoimmune conditions or those in low-resource settings. Notably, patients in the trial with favorable-risk status demonstrated survival benefits comparable to or exceeding current immunotherapy combinations.